lobbying_activities: 798419
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 798419 | 1496e54e-5d39-43f0-872e-46f86f3d94c8 | Q2 | THE DUBERSTEIN GROUP INC. | 12675 | AMERICA'S HEALTH INSURANCE PLANS | 2009 | second_quarter | PHA | Antitrust exemption for pharmacies - HR 1204, To ensure and foster continued patient safety and quality of care by making the antitrust laws apply to negotiations between groups of independent pharmacies and health plans and health insurance issuers (including health plans under parts C and D of the Medicare Program) in the same manner as such laws apply to protected activities under the National Labor Relations Act. Generic biologics - HR 1427, To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes; HR 1548, To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes; S 726, A bill to amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes; draft legislation re this issue (HELP/Kennedy Affordable Health Choices). Generic drugs - HR 1706, To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes; S 369, A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. | HOUSE OF REPRESENTATIVES,SENATE | 100000 | 0 | 0 | 2009-07-17T14:52:39-04:00 |